Tybourne Capital Management (hk)
HONG KONG, K3files as TYBOURNE CAPITAL MANAGEMENT (HK) LTD
$31m in 4 US stocks at the end of 30 September 2025. The top 10 are 100.0% of the money. It changed about 26.3% of the portfolio this quarter.
Value
$31m
Stocks
4
Top 10 share
100.0%
Turnover
26.3%
What changed this quarter
New
Bought for the first time this quarter.
None this quarter.
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
- Taysha Gene TherapiesTSHA39.1% of the fund-10%
- Zentalis PharmaceuticalsZNTL4.7% of the fund-35%
Sold out
Sold their entire stake.
- Bicycle TherapeuticsBCYC-100%
- Malibu BoatsMBUU-100%
Holdings
- Forte Biosciences
- Share
- 38.1%
- Value
- $12m
- Shares
- 786,647
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Taysha Gene TherapiesTSHA | 39.1% | $12m | 3,700,000 | -10% |
| Forte Biosciences | 38.1% | $12m | 786,647 | Held |
| AlumisALMS | 18.0% | $6m | 1,399,250 | Held |
| Zentalis PharmaceuticalsZNTL | 4.7% | $1m | 961,486 | -35% |
Over time and by industry
Value over time
Sep '25
Value is down 10.4% since 30 June 2025.
Where the money is
Health care61.9%
Other38.1%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.